Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Published 2018 Jul 7
Research is exploring GLP-1s potential treating conditions beyond weight loss and cardio related diseases
Ongoing research further explores their potential benefits in obesity, metabolic diseases such as type 2 diabetes, cardiovascular health, and cognitive and mental function
Exenatide LAR from Amylin/ AstraZeneca: A once-weekly injection of exenatide has been approved as of January 27, 2012 under the trademark Bydureon
All doses met primary and key secondary endpoints
%25201.png)
US$ 23.99
US$ 23.04
US$ 28.76
